Acomplia diet drug

 ACOMPLIA - GENERIC ACOMPLIA ( Rimonabant )

Rimonabant (Generic Acomplia) is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges, such as smoking. This is a non-control weightloss solution that in one study, helped people who were overweight drop an average of 20 pounds, and was found to be very useful for patients who suffer from obesity.

Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and
abnormal levels of fat in the blood. Patients with large waist
circumference (102 cm in men and 88 cm in women) will
mostly benefit from taking Acomplia.

H ow does it work?

Acomplia tablets contain the active ingredient rimonabant, which is a type of medicine called a cannabinoid-1 receptor antagonist. It is used to aid weight loss in people who are obese or overweight.

Rimonabant works by blocking receptors called cannabinoid-1 receptors (CB1). These are found in the brain, fat tissue, digestive system, liver and muscles.

The CB1 receptors are part of a system in the body called the endocannabinoid system. This system has only recently been discovered and explored. It is involved in regulating energy balance, sugar and fat metabolism and body weight.

The CB1 receptors found in a particular area of the brain called the mesolimbic system are involved in controlling our intake of highly palatable, sweet or fatty foods. Overactivation of the CB1 receptors is associated with increased appetite, cravings for food and fat build-up.

If you take the diet drug Acomplia, you can keep off lost pounds only if you keep taking it, researchers say.

And those who stay on the drug keep their smaller waist, lower blood-fat levels, and higher good cholesterol levels.

If you don’t cut your calories, Acomplia won’t help you lose weight. But obese and overweight people who do eat less lost an average of 14 pounds if they were able to take Acomplia for one year. That’s 10.5 pounds more than those who ate less and got an inactive placebo pill, reports F. Xavier Pi-Sunyer, MD, professor of medicine at Columbia University and chief of endocrinology at St. Luke’s-Roosevelt Hospital, New York.

“I think it is exciting, because [Acomplia] has a new mechanism of action, and seems as effective [for weight loss] as any drug on the market,” Pi-Sunyer tells WebMD. “[Acomplia] does a reasonable job of modest weight loss.”

The results, first reported in 2004, appear in the Feb. 15 issue of The Journal of the American Medical Association.

The FDA has not yet approved Acomplia, but is expected to act soon. In clinical trials, the drug has helped people lose weight. Obese people seem to have an overactive cannabinoid system. By partially shutting this system down, Acomplia helps people resist the craving for highly palatable food popularly known as ‘the munchies.’